Ignite Creation Date:
2025-12-24 @ 4:54 PM
Ignite Modification Date:
2026-01-25 @ 3:11 PM
Study NCT ID:
NCT03727750
Status:
COMPLETED
Last Update Posted:
2022-03-25
First Post:
2018-09-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-07-03
Start Date Type:
ACTUAL
Primary Completion Date:
2021-04-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-04-27
Completion Date Type:
ACTUAL
First Submit Date:
2018-09-28
First Submit QC Date:
None
Study First Post Date:
2018-11-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-02-28
Results First Submit QC Date:
None
Results First Post Date:
2022-03-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-28
Last Update Post Date:
2022-03-25
Last Update Post Date Type:
ACTUAL